Bacteremia and infective endocarditis in patients on hemodialysis

American Journal of the Medical Sciences

Volumn 327, Issue 5, 2004, Pages 242-249

  Maraj, Suraj ^a   Jacobs, Larry E ^a   Maraj, Rajiv ^a   Kotler, Morris N ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Bacteremia; End stage renal disease; Hemodialysis; Infective endocarditis

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; CHLORHEXIDINE; MINOCYCLINE; NEOMYCIN; POLYMYXIN; PSEUDOMONIC ACID; RIFAMPICIN; SULFADIAZINE SILVER; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; CATHETER; CLINICAL FEATURE; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRAVENOUS DRUG ABUSE; KIDNEY FAILURE; NEUTROPENIA; PATHOGENESIS; PATIENT CARE; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK FACTOR; SIDE EFFECT; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; UNITED STATES;

EID: 2442674411     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200405000-00019     Document Type: Review

References (53)

1. Vijayvargiya R, Veis JH. Antibiotic-resistant endocarditis in a hemodialysis patient. J Am Soc Nephrol 1996;7:536-42.
2. McCarthy JT, Steckelberg JM. Infective endocarditis in patients receiving long-term hemodialysis. Mayo Clin Proc 2000;75:1008-14.
3. Powe NR, Jaar B, Furth SL, et al. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 1999;55:1081-90.
4. Haag-Weber M, Horl WH. Uremia and infection: mechanisms of impaired cellular host defense. Nephron 1993;63:125-31.
5. Kessler M, Hoen B, Mayeux D, et al. Bacteremia in patients on chronic hemodialysis. Nephron 1993;64:95-100.
6. Boelaert JR, Daneels RF, Schurgers ML, et al. Iron overload in haemodialysis patients increases the risk of bacteremia. A prospective study. Nephrol Dial Transplant 1990;5:130-4.
7. Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002;57:457-61.
8. Nassar GM, Ayus JC. Infectious complications of the hemodialysis access. Kidney Int 2001;60:1-13.
9. Winsett OE, Wolma FJ. Complications of vascular access for hemodialysis. South Med J 1985;78:513-7.
10. Berkoben M, Schwab SJ. Hemodialysis vascular access. In: Henrich WL, editor. Principles and practice of dialysis. 2nd ed. Lippincott Williams & Wilkins; 1999. p. 41-59.
11. Zibari GB, Rohr MS, Landreneau MD, et al. Complications from permanent hemodialysis vascular access. Surgery 1988;104:681-6.
12. Munda R, First MR, Alexander JW, et al. Polytetrafluoroethylene graft survival in hemodialysis. JAMA 1983;249:219-22.
13. Robinson DL, Fowler VG, Sexton DJ, et al. Bacterial endocarditis in hemodialysis patients. Am J Kidney Dis 1997;30:521-4.
14. Maraj S, Jacobs LE, Kung SC, et al. Epidemiology and outcomes of infective endocarditis in hemodialyzed patients. Am J Med Sci 2002;324:254-60.
15. Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9:869-76.
16. Straumann E, Meyer B, Mistele M, et al. Aortic and mitral valve disease in patients with end stage renal failure in long-term hemodialysis. Br Heart J 1992;67:236-9.
17. Sexton DJ. Vascular access infections in patients undergoing dialysis with special emphasis on the role and treatment of Staphylococcus aureus. Infect Dis Clin North Am 2001;15:731-42.
18. Watanakunakorn C, Burkert T. Infective endocarditis at a large community teaching hospital: a review of 210 episodes. Medicine 1993;72:90-102.
19. Fowler VG Jr., McIntyre LM, Yeaman MR, et al. In vitro resistance to thrombin-induced platelet microbicidal protein in isolates of Staphylococcus aureus from endocarditis patients correlates with an intravascular device source. J Infect Dis 2000;182:1251-4.
20. Kamaraju S, Nelson K, Williams DN, et al. Staphylococcus lugdunensis pulmonary valve endocarditis in a patient on chronic hemodialysis. Am J Nephrol 1999;19:605-8.
21. Ferrer C, Jakob E, Pastorino G, et al. Right-sided bacterial endocarditis due to Flavobacterium odoratum in a patient on chronic hemodialysis. Am J Nephrol 1995;15:82-4.
22. Singh M, Bofinger A, Cave G, et al. Mycobacterium fortuitum endocarditis in a patient with chronic renal failure on hemodialysis. Pathology 1992;24:197-200.
23. Sungur C, Sungur A, Gedikoglu G, et al. Fatal Brucella melitensis endocarditis in a hemodialysis patient. Nephron 1994;67:234-5.
24. Turner HR, Taylor MR, Lockwood WR. Branhamella catarrhalis endocarditis in a patient receiving hemodialysis. South Med J 1985;78:1021-2.
25. Martinez-Vea A, Costa J, Garcia C, et al. Corynebacterium group JK endocarditis in a haemodialysis patient. Nephrol Dial Transplant 1993;8:177-9.
26. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96:200-9.
27. Mohamed M, Habte-Gabr E, Mueller W. Infected arteriovenous hemodialysis graft presenting as left and right infective endocarditis. Am J Nephrol 1995;15:521-3.
28. Shapiro SM, Young E, De Guzman S, et al. Transesophageal echocardiography in diagnosis of infective endocarditis. Chest 1994;105:377-82.
29. Daniel WG, Erbel R, Kasper W, et al. Safety of transesophageal echocardiography: a multicenter survey of 10,419 examinations. Circulation 1991;83:817-21.
30. Cormier B, Vahanian A. Echocardiography and indications for surgery. Eur Heart J 1995;16(Suppl B):68-71.
31. Heidenreich PA, Masoudi FA, Maini B, et al. Echocardiography in patients with suspected endocarditis: a cost-effectiveness analysis. Am J Med 1999;107:198-208.
32. Leonard A, Leopoldo R, Shapiro FL. Bacterial endocarditis in regularly dialyzed patients. Kidney Int 1973;4:407-22.
33. Zamora JL, Burdine JT, Karlberg H, et al. Cardiac surgery in patients with end-stage renal disease. Ann Thorac Surg 1986;42:113-7.
34. Reid CL, Rahhimtoola SH. Infective endocarditis in chronic renal failure. In: O'Rourke RA, Brenner BM, Stein JH, eds. The heart and renal disease. Contemporary issues in nephrology series. Edinburgh: Churchill Livingstone; 1984. p. 189-208.
35. Cross AS. Infective endocarditis and access site infections in patients on hemodialysis. Medicine (Baltimore) 1976;55:453-66.
36. Foley RN, Parfrey PS, Kent GM, et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912-6.
37. US Renal Data System. USRDS 2000 annual data report: atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000.
38. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections a randomized, double-blind trial. Ann Intern Med 1997;127:267-74.
39. Eknoyan G, Levin NW, Eschbach JW, et al. NKF-K/DOQI clinical practice guidelines. New York: National Kidney Foundation. Available at: URL: http://www.kidney.org/professionals/doqi/guidelines/doqi[lowen]uptoc.html
40. Maki DG, Stolz SM, Wheeler S, et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997;127:257-66.
41. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992;15:197-210.
42. Boelaert JR. Staphylococcus aureus infection in haemodialysis patients. Mupirocin as a topical strategy against nasal carriage: a review. J Chemother 1994;6(Suppl. 2):19-24.
43. Sesso R, Barbosa D, Leme IL, et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin treatment. J Am Soc Nephrol 1998;9:1085-92.
44. Logghe C, Van Ossel C, D'Hoore W, et al. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J Hosp Infect 1997;37:145-56.
45. Trerotola SO, Johnson MS, Shah H, et al. Tunneled hemodialysis catheters: use of silver-coated catheter for prevention of infection: a randomized study. Radiology 1998;207:491-6.
46. Besnier JM, Choutet P. Medical treatment of infective endocarditis: general principles. Eur Heart J 1995;16(Suppl B):72-4.
47. Atta MG, Eustace JA, Song X, et al. Outpatient vancomycin use and vancomycin-resistant enterococcal colonization in maintenance dialysis patients. Kidney Int 2001;59:718-24.
48. Capdevila JA, Segarra A, Planes AM, et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Trans 1993;8:231-4.
49. Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998;54:1684-9.
50. Shaffer D. Catheter-related sepsis complicating long-term, tunnelled central venous dialysis catheters: management by guidewire exchange. Am J Kidney Dis 1995;25:593-6.
51. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999;10:1045-9.
52. Tanriover B, Carlton D, Saddekni S, et al. Bacteremia associated with tunneled dialysis catheters: comparison of two treatment strategies. Kidney Int 2000;57:2151-5.
53. Anonymous. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 1998;32:1486-582.